Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study.

Trial Profile

Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Hodgkin's disease; Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 29 Jun 2011 Additional lead trial center identified as reported by ClinicalTrials.gov.
    • 27 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top